Lung Volume Segment to Account for Largest Share in Pulmonary Function Testing Systems Market During 2022-2028
According to the research study titled ""the Pulmonary Function Testing Systems Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Test Type, Component, Application, and End User,"" the market is expected to reach US$ 401.83 million by 2028 from US$ 274.10 million in 2022 with an estimated CAGR of 6.6% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
In terms of revenue, Europe holds the second-largest share of the pulmonary function testing systems market in 2021. In Europe, Germany accounted for the largest market share in 2022. The UK is expected to register the highest CAGR in the Europe pulmonary function testing systems market from 2022 to 2028. According to the Public Library of Science (PLoS) report, chronic obstructive pulmonary disease (COPD) has grown to become the fourth leading cause of death globally. The current prevalence of COPD in Germany ranges from 1.3% to 13.2%. Also, the economic burden of COPD on the German healthcare system is high as the treatment for COPD is cost-intensive and is associated with high chances of work impairment..
Moreover, CF affects approximately one in 2,500 newborns in Germany. Therefore, for treating COPD among the German population, Statutory health insurance (SHI) acts as a core component of the German healthcare system. Additionally, cystic fibrosis (CF), a genetic condition, affects more than 8,000 children, adolescents, and adults in Germany as per the statistics revealed by Deutsches Zentrum für Lungenforschung (German Center for Lung Research, DZL) e. V. report. The SHI funds offer structured treatment programs intended for certain chronic diseases, including diabetes (type 1 and 2), breast cancer, coronary artery disease, asthma, and COPD. Further, with the high prevalence of asthma among the German population, the economic burden of the disease acts as a significant challenge for SHI. For example, pharmacotherapy and outpatient care account for significant healthcare costs related to asthma, with costs for in-patient care still considerable, with 23% of the asthma-related costs in Germany. With the high prevalence and healthcare expenditure of pulmonary disease among the German population, there is accelerating demand for pulmonary function testing systems.
Market Opportunities
Home Healthcare Pulmonary Function Testing Systems
The majority of lung function tests require specialized equipment that is only available for medical settings. However, at-home spirometers are available for patients with some lung diseases. For example, new approaches have enabled some at-home spirometry to be performed with the assistance of a tablet or smartphone. Various top companies are launching innovative products, particularly to perform sophisticated lung assessments at patients' homes. For example, in 2016, American Respiratory Labs (ARL), a California-based mobile pulmonary function testing company, launched the ""EasyOne PRO"" product to perform sophisticated lung assessments at patients' homes. The EasyOne Pro performs DLCO testing, spirometry, and full lung volumes anywhere in just 20 minutes. Moreover, EasyOne Pro provides accurate results through reliable ultrasound technology by eliminating calibration and maintenance costs. Further, after testing, the software enables American Respiratory Labs (ARL) to import PFT results into patients' electronic health records. Additionally, at-home spirometry is often performed to assess a patient's oxygen needs. Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) testing can determine shortness of breath caused due to respiratory or cardiac disease and differentiate between asthma and chronic obstructive pulmonary disorder (COPD) for appropriate treatment. Therefore, commercializing home healthcare pulmonary function testing systems products globally will offer lucrative market opportunities for the growth of the pulmonary function testing systems market in the forthcoming years.
Based on test type, the pulmonary function testing systems market is categorized into spirometry, lung volume, gas exchange testing, maximal voluntary ventilation, oxygen titration test, and others. The spirometry segment accounted for a 44.32% share of the pulmonary function testing systems market in 2022. Additionally, the lung volume segment is expected to register the highest CAGR during the forecast period. Spirometry is a medical test used to measure certain lung conditions. The test is used to diagnose and monitor the lungs' capacity by measuring how much air can breathe out in one forced breath. The test is carried out with the help of medical devices called spirometry systems (PFT). The product used advanced software technology to provide accurate results.
The device can assist in diagnosing various respiratory diseases, such as obstructive chronic lung disease, emphysema, asthma, and other breathing disorders, for screening in an occupational environment. It is the gold standard for COPD diagnosis; however, the bulky size, complex functionality, and the need for regular maintenance are negatively impacting the acceptance of conventional spirometers by medical practitioners.
For instance, RMS Helios 401 is PC-based equipment is capable of diagnosing, differentiating and measuring various pulmonary diseases. The Helios series comes with a highly advanced and user-friendly software offering 34 parameter readings, pre-post bronchodilation results, percentage improvement and lung age calculations.
COSMED Srl, MGC Diagnostics Corp, Morgan Scientific Inc, Minato Medical Science Co Ltd, Schiller AG, Chest MI Inc, Vyaire Medical Inc, ndd Medical Technologies Inc, PulmOne Advanced Medical Devices Ltd, and KoKo PFT Ltd are among the leading companies operating in the global pulmonary function testing systems market.
Based on geography, the global pulmonary function testing systems market is primarily segmented into North America, Europe, Asia Pacific, Middle East & Africa (MEA), and South & Central America. The North America pulmonary function testing systems market is further segmented into the US, Canada, and Mexico. The Europe pulmonary function testing systems market is subsegmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Asia Pacific pulmonary function testing systems market is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. The pulmonary function testing systems market in the MEA is further segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. The South & Central America pulmonary function testing systems market is subsegmented into Brazil, Argentina, and the Rest of South & Central America.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:sales@premiummarketinsights.com